BioVie Inc
BIVI
NASDAQ
Biotechnology
$1.40
USD
-0.16 (-10.26%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.88M
Volume 2.0M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-22.07M
TTM
-25.8%
YoY
Operating Cash Flow
$-19.02M
TTM
+0.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.4 | 2.3 | 1.9 | 2.2 | 2.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.7 | 5.3 | 6.3 | 5.4 | 5.7 |
Operating Income | -3.7 | -5.3 | -6.3 | -5.4 | -5.7 |
EBITDA | -3.6 | -5.2 | -6.2 | -5.3 | -5.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
Income Before Income Taxes | -3.5 | -5.1 | -6.1 | -5.3 | -5.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.5 | -5.1 | -6.1 | -5.3 | -5.6 |
Consolidated Net Income / Loss | -3.5 | -5.1 | -6.1 | -5.3 | -5.6 |
Net Income Attributable to Common Shareholders | -3.5 | -5.1 | -6.1 | -5.3 | -5.6 |
Basic EPS | -$1.89 | -$0.98 | -$0.77 | -$0.70 | -$0.68 |
Diluted EPS | -$1.89 | -$0.98 | -$0.77 | -$0.70 | -$0.68 |
Basic Shares Outstanding | 1.8M | 5.2M | 7.9M | 7.5M | 8.3M |
Diluted Shares Outstanding | 1.8M | 5.2M | 7.9M | 7.5M | 8.3M |